Insomnia - newer hypnotic drugs (TA77)
NICE has made the following recommendations about the use of zaleplon, zolpidem and zopiclone to treat insomnia.
- NICE recommends that doctors should consider using non-medicine treatments, and then, if they think that a hypnotic medicine is the appropriate way to treat severe insomnia that is interfering with normal daily life, they should prescribe one for only short periods of time and strictly according to the licence for the drug.
- Because there is no firm evidence of differences in the effects of zaleplon, zolpidem, zopiclone and the shorter-acting benzodiazepines, NICE recommends that doctors should prescribe the cheapest drug, taking into account the daily dose required and the cost for each dose.
- Treatment should only be changed from one of these hypnotics to another if side effects occur that are directly related to the medicine.
- If treatment with one of these hypnotic medicines does not work, the doctor should not prescribe one of the others.
- Insomnia - newer hypnotic drugs: review decision - August 2010
- Review Proposal - May 2010
- Assessment report: The clinical and cost-effectiveness of zaleplon, zolpidem and zopiclone for the management of insomnia
- NICE issues guidance on the use of drugs for the management of insomnia
- TA77 Insomnia - newer hypnotic drugs: distribution list
- Review proposal - September 2007
- Review decision - November 2007
- Appendix A - Matrix of consultees and commentators.
This page was last updated: 28 September 2011
Information for the public
Implementation tools and resources
- None available
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.